Treatment recommendations for patients with vitiligo during COVID-19
dc.contributor.author | Rodrigues, Michelle | |
dc.contributor.author | Pandya, Amit G. | |
dc.contributor.author | Hamzavi, Iltefat | |
dc.contributor.author | Ezzedine, Khaled | |
dc.contributor.author | Bekkenk, Marcel W. | |
dc.contributor.author | Harris, John E. | |
dc.date | 2022-08-11T08:08:10.000 | |
dc.date.accessioned | 2022-08-23T15:45:02Z | |
dc.date.available | 2022-08-23T15:45:02Z | |
dc.date.issued | 2021-05-24 | |
dc.date.submitted | 2021-06-14 | |
dc.identifier.citation | <p>Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol. 2021 May 24. doi: 10.1111/ajd.13610. Epub ahead of print. PMID: 34028796. <a href="https://doi.org/10.1111/ajd.13610">Link to article on publisher's site</a></p> | |
dc.identifier.issn | 0004-8380 (Linking) | |
dc.identifier.doi | 10.1111/ajd.13610 | |
dc.identifier.pmid | 34028796 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/27447 | |
dc.description.abstract | The World Health Organization declared a global pandemic on 12 March 2020 due to the worldwide spread of COVID-19, caused by SARS-CoV-2.1 Vitiligo is an autoimmune disease causing skin depigmentation affecting 0.5%–2% of the population. We do not project an increased risk of infection from COVID-19 in those with vitiligo, as the immune system of such individuals is not compromised and there is currently no evidence that the virus infects melanocytes. However, some patients may have treatment-related immunosuppression and some may have to access in-office narrow band ultraviolet light B (NB-UVB), which could increase their risk of developing COVID-19. At this time, there is a need to balance treatment for vitiligo with the need to reduce exposure to SARS-CoV-2. We have thus outlined the following treatment considerations to guide clinicians in the treatment of their vitiligo patients. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34028796&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.relation.url | https://doi.org/10.1111/ajd.13610 | |
dc.subject | vitiligo | |
dc.subject | COVID-19 | |
dc.subject | Dermatology | |
dc.subject | Health Services Administration | |
dc.subject | Infectious Disease | |
dc.subject | Skin and Connective Tissue Diseases | |
dc.subject | Therapeutics | |
dc.subject | Virus Diseases | |
dc.title | Treatment recommendations for patients with vitiligo during COVID-19 | |
dc.type | Letter to the Editor | |
dc.source.journaltitle | The Australasian journal of dermatology | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/covid19/248 | |
dc.identifier.contextkey | 23348824 | |
html.description.abstract | <p>The World Health Organization declared a global pandemic on 12 March 2020 due to the worldwide spread of COVID-19, caused by SARS-CoV-2.<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/ajd.13610#ajd13610-bib-0001" id="x-x-ajd13610-bib-0001R">1</a></sup> Vitiligo is an autoimmune disease causing skin depigmentation affecting 0.5%–2% of the population. We do not project an increased risk of infection from COVID-19 in those with vitiligo, as the immune system of such individuals is not compromised and there is currently no evidence that the virus infects melanocytes. However, some patients may have treatment-related immunosuppression and some may have to access in-office narrow band ultraviolet light B (NB-UVB), which could increase their risk of developing COVID-19. At this time, there is a need to balance treatment for vitiligo with the need to reduce exposure to SARS-CoV-2. We have thus outlined the following treatment considerations to guide clinicians in the treatment of their vitiligo patients.</p> | |
dc.identifier.submissionpath | covid19/248 | |
dc.contributor.department | Department of Dermatology |